Tod H. Mikuriya

Last updated
Tod H. Mikuriya
Author Dr. Tod Mikuriya.jpg
Born(1933-09-20)20 September 1933
Died20 May 2007(2007-05-20) (aged 73)
Known forAdvocate for legalization and use of marijuana for medical purposes.
Medical career
ProfessionPsychiatrist
InstitutionsCalifornia Cannabis Research Medical Group, Society of Cannabis Clinicians

Tod Hiro Mikuriya (20 September 1933 20 May 2007) was an American medical doctor and psychiatrist. [1] Known as an outspoken advocate for the use of cannabis for medical purposes and its legalization, [2] he is often regarded as the grandfather of the medical cannabis movement in the United States. [3] [4] [5]

Contents

Personal life

Mikuriya was born at his Aunt Mary Schwenk Wallace's home in Brownsville, Pennsylvania, [6] from German teacher Anna Schwenk and civil engineer Tadafumi Mikuriya, an Issei descendant of the Japanese samurai nobility. [7]

Growing up in the Quaker community of Fallsington, Pennsylvania and attending Quaker schools (George School, Haverford College) it was the compromise chosen by his parents that the three Mikuriya children were raised as Quakers. "The Quakers were proprietors of the Underground Railway, I’m proud to say. The cannabis prohibition has the same dynamics as the bigotry and racism my family and I experienced starting on 7 December 1941, when we were transformed from normal-but-different people into war-criminal surrogates." [8] In a 1998 interview, Mikuriya (whose father was a converted Christian and whose mother a follower of the Baháʼí Faith), made a connection between his family background and his views in relation to cannabis.[ citation needed ] Mikuriya claimed he first heard of cannabis in a children's book in 1959. [9]

In 1951, Mikuriya graduated from a private Quaker preparatory school. He graduated a bachelor's degree from Reed College in 1956 and was drafted into the Army the following year. Mikuriya served at Brooke Army Hospital psychiatric ward before graduating his medical degree in 1962 at Temple University, with an internship at Southern Pacific Hospital (San Francisco) and residencies in psychiatry at Oregon State Hospital and at Mendocino State Hospital.

Mikuriya died at his home in Berkeley, California on 20 May 2007, [10] aged 73, after a long battle with cancer. [2]

Professional career

Mikuriya first directed a center for the treatment of drug addiction in Princeton, New Jersey (1966–1967) before being appointed director of non-classified marijuana research for the National Institute of Mental Health Center for Narcotics and Drug Abuse Studies in 1967. [11]

In the late 1960s and early 1970s, he authored a number of academic publications creating the debate on the therapeutic use of cannabis within the medical community, [12] [13] [14] including proposing cannabis as a substitution agent [15] as well as on issues related to the legality of cannabis. [16] [17]

His 1972 self-published book Marijuana Medical Papers 1839–1972 became a landmark in the modern movement for the legalization of Medical marijuana. Collected from the reference section at the National Library of Medicine it was saved from complete oblivion. [7] Much to the irritation of cannabis prohibitionists, this medical intelligence has been restored for possible alternative medical applications. Mikuriya continued publicating in the 1970s and 1980s. [18] [19] [20]

Clinical practice

Until his death in May 2007, he continued in private psychiatric practice limited to cannabis clinical consultation. He approved marijuana for medical purposes in over nine thousand patients, not solely in terminal cases, but also alleviation of physical and emotional pain in non-terminal cases. The legal situation is extremely complex (see legal history of marijuana in the United States).

His practices are controversial and have drawn him into conflict with authorities. He was on five years probation with the Medical Board of California resulting from prosecutorial manipulation and conspiracy with local, state, and federal law enforcement vendetta starting in 2000. No patients were harmed. There were no complaints from patients, families or community physicians. Only law enforcement in eleven rural northern California counties responded to solicitation by Medical Board investigators and officials in the California Attorney General's office. [21]

Political involvement

Mikuriya vas involved early on in political and civil movements focused on changing cannabis laws. [7] In 1971, Mikuriya joined the group Amorphia, "a special interest group that was spearheading the California Marijuana Initiative." [3] He took part in the redaction of the failed California Prop. 19 in 1972, and helped Dennis Peron redact San Francisco's Prop P which passed in 1991.

He is maybe more known for his involvement on 1996 California Proposition 215. He declared: "As one of the authors of the Prop 215, my claim to fame is getting the phrase ‘for any other condition that Cannabis is helpful’ included." [3]

In 1980, he ran in the House of Representatives elections as a member of the Libertarian Party, against incumbent Ron Dellums, a Democrat, and Republican Charles V. Hughes for California's 8th congressional district seat. He lost, with 10,465 votes, to Dellums' 108,380 and Hughes' 76,580.

Creation of the Society of Cannabis Clinicians

In 1999, Mikuriya founded the California Cannabis Research Medical Group to help physicians share and exchange data about cannabis use by their patients. [22] In 2004, the CCRMG formed the Society of Cannabis Clinicians (SCC) to facilitate voluntary medical standards for physician-approved cannabis under California law (HSC §11362.5). [23]

Related Research Articles

<span class="mw-page-title-main">Tetrahydrocannabinol</span> Chemical compound

Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers, the term THC usually refers to the Delta-9-THC isomer with chemical name (−)-trans9-tetrahydrocannabinol. THC is a terpenoid found in cannabis and, like many pharmacologically active phytochemicals, it is assumed to be involved in the plant's evolutionary adaptation against insect predation, ultraviolet light, and environmental stress. THC was first discovered and isolated by Israeli chemist Raphael Mechoulam in Israel in 1964. It was found that, when smoked, THC is absorbed into the bloodstream and travels to the brain, attaching itself to endocannabinoid receptors located in the cerebral cortex, cerebellum, and basal ganglia. These are the parts of the brain responsible for thinking, memory, pleasure, coordination and movement.

<span class="mw-page-title-main">Effects of cannabis</span> Effects resulting from the use of cannabis

The effects of cannabis are caused by chemical compounds in the cannabis plant, including 113 different cannabinoids such as tetrahydrocannabinol (THC) and 120 terpenes, which allow its drug to have various psychological and physiological effects on the human body. Different plants of the genus Cannabis contain different and often unpredictable concentrations of THC and other cannabinoids and hundreds of other molecules that have a pharmacological effect, so the final net effect cannot reliably be foreseen.

<span class="mw-page-title-main">Medical cannabis</span> Marijuana used medicinally

Medical cannabis, or medical marijuana (MMJ), is cannabis and cannabinoids that are prescribed by physicians for their patients. The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.

<span class="mw-page-title-main">1996 California Proposition 215</span> California law permitting medical marijuana

Proposition 215, or the Compassionate Use Act of 1996, is a California law permitting the use of medical cannabis despite marijuana's lack of the normal Food and Drug Administration testing for safety and efficacy. It was enacted, on November 5, 1996, by means of the initiative process, and passed with 5,382,915 (55.6%) votes in favor and 4,301,960 (44.4%) against.

<span class="mw-page-title-main">Cannabis (drug)</span> Psychoactive drug from the cannabis plant

Cannabis, also known as marijuana among other names, is a psychoactive drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.

<span class="mw-page-title-main">Cannabis tea</span> Cannabis-infused drink

Cannabis tea is a cannabis-infused drink prepared by steeping various parts of the cannabis plant in hot or cold water. Cannabis tea is commonly recognized as an alternative form of preparation and consumption of the cannabis plant, more popularly known as marijuana, pot, or weed. This plant has long been recognized as an herbal medicine employed by health professionals worldwide to ease symptoms of disease, as well as a psychoactive drug used recreationally and in spiritual traditions. Though less commonly practiced than popular methods like smoking or consuming edibles, drinking cannabis tea can produce comparable physical and mental therapeutic effects. Such effects are largely attributed to the THC and CBD content of the tea, levels of which are drastically dependent on individual preparation techniques involving volume, amount of cannabis, and boiling time. Also in common with these administration forms of cannabis is the heating component performed before usage. Due to the rather uncommon nature of this particular practice of cannabis consumption in modern times as well as the legality of cannabis throughout the World, the research available on the composition of cannabis tea is limited and based broadly around what is known of cannabis as it exists botanically.

<span class="mw-page-title-main">Fred Gardner (activist)</span> American political organizer and author

Fred Gardner is an American political organizer and author best known for his opposition to the Vietnam War and his writings about the medical marijuana movement in the United States.

The Society of Cannabis Clinicians (SCC) is a 501(c)(3) non-profit organization registered in the United States, dedicated to educating healthcare professionals about the medical use of cannabis. Its mission is to unite into one association members of the various medical specialties and allied professionals with this common purpose. SCC is one of the oldest active organization of its kind, and one of the few global non-profit medical societies related to cannabis and cannabinoids, along with the International Cannabinoid Research Society and the International Association for Cannabinoid Medicines.

<span class="mw-page-title-main">Legalization of non-medical cannabis in the United States</span> Legalization of marijuana in the United States

In the United States, the non-medical use of cannabis is legalized in 23 states and decriminalized in 8 states, as of May 2023. Decriminalization refers to a policy of reduced penalties for cannabis offenses, typically involving a civil penalty for possessing small amounts, instead of criminal prosecution or the threat of arrest. In jurisdictions without penalty the policy is referred to as legalization, although the term decriminalization is sometimes used for this purpose as well.

The American Medical Marijuana Association (AMMA) is an organization formed to promote and protect legal access to medical marijuana.

Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.

<span class="mw-page-title-main">11-Hydroxy-THC</span> Chemical compound

11-Hydroxy-Δ9-tetrahydrocannabinol, usually referred to as 11-hydroxy-THC is the main active metabolite of tetrahydrocannabinol (THC), which is formed in the body after Δ9-THC is consumed.

<span class="mw-page-title-main">Drug policy of California</span> Overview of the drug policy of the U.S. state of California

Drug policy of California refers to the policy on various classes and kinds of drugs in the U.S. state of California. Cannabis possession has been legalized with the Adult Use of Marijuana Act, passed in November 2016, with recreational sales starting January of the next year. With respect to many controlled substances, terms such as illegal and prohibited do not include their authorized possession or sale as laid out by applicable laws.

Ethylene glycol poisoning is poisoning caused by drinking ethylene glycol. Early symptoms include intoxication, vomiting and abdominal pain. Later symptoms may include a decreased level of consciousness, headache, and seizures. Long term outcomes may include kidney failure and brain damage. Toxicity and death may occur after drinking even in a small amount as ethylene glycol is more toxic than other diols.

The history of medicinal cannabis goes back to the ancient times. Ancient physicians in many parts of the world mixed cannabis into medicines to treat pain and other ailments. In the 19th century, cannabis was introduced for therapeutic use in Western Medicine. Since then, there have been several advancements in how the drug is administered. Initially, cannabis was reduced to a powder and mixed with wine for administration. In the 1970s, synthetic THC was created to be administered as the drug Marinol in a capsule. However, the main mode of administration for cannabis is smoking because its effects are almost immediate when the smoke is inhaled. Between 1996 and 1999, eight U.S. states supported cannabis prescriptions opposing policies of the federal government. Most people who are prescribed marijuana for medical purposes use it to alleviate severe pain.

<span class="mw-page-title-main">Steven Seifert</span> American medical toxicologist

Steven A. Seifert (1950–2022) was an American medical toxicologist. He was a professor of emergency medicine at the University of New Mexico, as well as the medical director of the New Mexico Poison and Drug Information Center. Since 2017, he was the editor-in-chief of Clinical Toxicology. He was also a jazz tenor saxophonist.

Medical cannabis research includes any medical research on using cannabis. Different countries conduct and respond to medical cannabis research in different ways.

Occupational health concerns over the use of cannabis among workers are becoming increasingly important as cannabis becomes legal in more areas of the US. Of note, employers have concerns of workers either coming to work acutely impaired or recent use of cannabis still being detected in the body. Employment issues such as ADA law as it relates to accommodations for cannabis, paying unemployment benefits or paying out workers compensation benefits and disability claims are all important issues. While federal law still prohibits use, employers in different states have taken different stances based on whether they are federal contractors, perform safety sensitive work or whether the cannabis use is acutely impairing the employee.

<span class="mw-page-title-main">Michael Krawitz</span> US Air force veteran

Michael Alan Krawitz is a US Air force veteran, Executive Director of the non-profit Veterans for Medical Cannabis Access, researcher on the history of medical cannabis, and international advocate for cannabis policy reform with FAAAT think & do tank and the International Association for Cannabinoid Medicines.

The International Association for Cannabinoid Medicines (IACM), formerly known as the International Association for Cannabis as a Medicine, is a non-profit scientific society founded in Cologne in 2000 and dedicated to the advancement of knowledge of cannabis and cannabinoid medicines among medical professionals. IACM is one of the few global non-profit medical societies or associations related to cannabis and Cannabinoids, along with the Society of Cannabis Clinicians and the International Cannabinoid Research Society.

References

  1. "Tod Mikuriya, MD — Notes for a Biography". O'Shaughnessy's Journal. 2008. Retrieved 2022-12-25.
  2. 1 2 Gardner, Fred (25 May 2007). "Tod Mikuriya, 1933–2007". The Berkley Daily Planet. Retrieved 10 September 2009.
  3. 1 2 3 Buscher, Rob (2020). "Tod Mikuriya: JA Father of the Medical Marijuana Movement". Pacific Citizen (Japanese American Citizens League). Retrieved 2022-12-25.
  4. Weinberg, Bill; Now, Cannabis (2020-03-08). "Tod Mikuriya: Grandfather of Medical Marijuana". Cannabis Now. Retrieved 2022-12-25.
  5. Takakuwa, Kevin M.; Schears, Raquel M. (2019). "A History of the US Medical Cannabis Movement and Its Importance to Pediatricians: Science Versus Politics in Medicine's Greatest Catch-22". Clinical Pediatrics. 58 (14): 1473–1477. doi:10.1177/0009922819875550. ISSN   0009-9228. PMID   31538822. S2CID   202701649.
  6. Buscher, Rob (2020). "JA Father of the Medical Marijuana Movement". Pacific Citizen (Japanese American Citizens League). Retrieved 2022-12-25.
  7. 1 2 3 O’Hern, Megan; Rees, John P. (2020-02-25). "Tod Mikuriya Papers Now Available for Research". Circulating Now (Archives and Modern Manuscripts Program, History of Medicine Division, National Library of Medicine). Retrieved 2022-12-25.
  8. "Tod Mikuriya, 1933-2007. Category: Features from The Berkeley Daily Planet". www.berkeleydailyplanet.com. Retrieved 2023-01-20.
  9. Mikuriya, Tod, Video playlists of Tod Mikuriya interviews , retrieved 2022-12-25
  10. Fox, Margalit (2007-05-29). "Tod H. Mikuriya, 73, Dies; Backed Medical Marijuana". The New York Times . ISSN   0362-4331 . Retrieved 2022-12-25.
  11. Nelson, Valerie J. (2007). "Tod H. Mikuriya, 73; psychiatrist who championed legal medical marijuana". Los Angeles Times . Retrieved 2022-12-25.
  12. Mikuriya, Tod H. (1969). "Marijuana in medicine: past, present and future". California Medicine. 110 (1): 34–40. PMC   1503422 . PMID   4883504.
  13. Mikuriya, Tod H. (1975). "Nonmedical Drugs, Society and Medicine: A Perspective with Suggestions". Clinical Toxicology. 8 (2): 145–148. doi:10.3109/15563657508988060. ISSN   0009-9309. PMID   1149408.
  14. Greden, John F. (1974-04-22). "Marijuana: Medical Papers, 1839-1972". JAMA. 228 (4): 506–507. doi:10.1001/jama.1974.03230290054040. ISSN   0098-7484.
  15. Mikuriya, Tod H. (1970). "Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism". Medical Times. 98 (4): 187–191. ISSN   0025-7583. PMID   5422576.
  16. Mikuriya, Tod H. (1968). "Need for just marihuana laws". The American Journal of Psychiatry. 125 (6): 852–853. doi:10.1176/ajp.125.6.852. ISSN   0002-953X. PMID   5748869.
  17. Mikuriya, Tod H.; Jones, R. T. (1971). "Contemporary aspects of drug abuse; an editorial view". Clinical Toxicology. 4 (1): 119–127. doi:10.3109/15563657108990154. ISSN   0009-9309. PMID   5107069.
  18. Mikuriya, T. D. (1975). "Editorial. Marijuana: medical, social, and moral aspects". Clinical Toxicology. 8 (2): 233–237. doi:10.3109/15563657508988067. ISSN   0009-9309. PMID   1097169.
  19. Mikuriya, T. H.; Aldrich, M. R. (1988). "Cannabis 1988. Old drug, new dangers. The potency question". Journal of Psychoactive Drugs. 20 (1): 47–55. doi:10.1080/02791072.1988.10524371. ISSN   0279-1072. PMID   3292744.
  20. Mikuriya, Tod H. (1975). "Marijuana: Medical, Social, and Moral Aspects". Clinical Toxicology. 8 (2): 233–237. doi:10.3109/15563657508988067. ISSN   0009-9309. PMID   1097169.
  21. "Tod H. Mikuriya, 73, Dies; Backed Medical Marijuana". New York Times. May 29, 2007.
  22. "Tod Hiro Mikuriya '56". Reed Magazine | In Memoriam. Retrieved 2022-12-25.
  23. Takakuwa, Kevin M. (2020-04-11). "A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement". The International Journal on Drug Policy. 79: 102749. doi:10.1016/j.drugpo.2020.102749. ISSN   1873-4758. PMID   32289591. S2CID   215771647.

Further reading